Revolution Medicines announced plans to initiate a global, randomized phase III trial of its RAS inhibitor daraxonrasib as first-line treatment for metastatic pancreatic ductal adenocarcinoma, following positive phase I data demonstrating clinical activity. Daraxonrasib, granted breakthrough therapy designation, represents a promising targeted therapy in a notoriously difficult-to-treat cancer. The move sets the stage for a pivotal study with potential to change standard of care in pancreas cancer.